Company: ANTX
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0000950170-25-107301
Chunk: 11

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 6
Chunk 11
---
2002.

     31.2*
      
     Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     32.1*†
      
     Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     32.2*†
      
     Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     101.INS
      
     Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

     101.SCH
      
     Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document**

     104
      
     Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** The following materials are formatted in Inline XBRL (Extensible Business Reporting Language): (i) the cover page; (ii) the Condensed Balance Sheets as of June 30, 2025 and December 31, 2024; (iii) the Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024; (iv) the Condensed Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024; (vi) the Condensed Statements of Cash Flows for the six months ended June 30, 2025 and 2024; (vii) Notes to Unaudited Condensed Financial Statements tagged as blocks of text.